Table 1.
Patient and Tumor Characteristics
| Characteristic | N = 59 |
|---|---|
| Age at BrM diagnosis | |
| Median | 52 |
| Range | 32–85 |
| BrM subtype | |
| Triple negative | 12 (20.3%) |
| HER2+/HR- | 14 (23.7%) |
| HER2+/HR+ | 14 (23.7%) |
| HR+/HER2- | 18 (30.5%) |
| Unknown | 1 (1.7%) |
| Number of BrM | |
| One | 37 (62.7%) |
| More than 1 | 21 (35.6%) |
| Unknown | 1 (1.7%) |
| BrM size (cm) | |
| Median | 2.9 |
| Range | 0.3–6.2 |
| BrM location | |
| Frontal | 15 (25.4%) |
| Parietal | 13 (22%) |
| Temporal | 3 (5.1%) |
| Cerebellar | 25 (42.4%) |
| Occipital | 2 (3.4%) |
| Unknown | 1 (1.7%) |
| BrM grade | |
| 1 | 16 (27.1%) |
| 2 | 22 (37.3%) |
| 3 | 15 (25.4%) |
| Unknown | 6 (10.2%) |
| BrM symptoms | |
| Yes | 51 (86.4%) |
| No | 7 (11.9%) |
| Unknown | 1 (1.7%) |
| Other sites of metastases | |
| Lung | 19 (32.2%) |
| Liver | 13 (22%) |
| Lymph node | 11 (18.6%) |
| Bone | 22 (37.3%) |
| Chest wall | 2 (3.4%) |
| Other | 4 (6.8%) |
| Radiotherapy for BrM | |
| Yes | 52 (88.1%) |
| No | 3 (5.1%) |
| Unknown | 4 (6.8%) |
| Systemic therapy for metastatic disease prior to BrM | |
| Chemotherapy | 9 (15.3%) |
| Herceptin-based treatment | 10 (16.9%) |
| Endocrine therapy | 4 (6.8%) |
| Unknown | 36 (61%) |
BrM, brain metastases.